Source: United Kingdom – Executive Government & Departments
A preprint, an unpublished non-peer reviewed study, looks at incidence of Cerebral Venous Thrombosis (CVT) after COVID-19, compared to incidence after receiving an mRNA COVID-19 vaccine (Pfizer or Moderna), or following influenza infection.
This Roundup accompanied an SMC Briefing.
Prof Paolo Madeddu, Professor of Experimental Cardiovascular Medicine at Bristol Medical School, University of Bristol, said:
“The major issue here is that the comparison showing the higher risk after Covid-19 does not exclude the possibility the pathogenesis is the same and therefore some common denominator should be searched.
“For instance, if the mechanism is the same, one can speculate that the high occurrence in covid-19 vs. vaccination is because the whole virus is more thrombogenic than the spike protein alone. These studies are important but seem to be focused on demonstrating the minor risk of vaccination instead of making efforts to explain the cause of complications, taking advantage of the similarities of the events in the two populations. I have previously expressed my opinion that the thrombogenic interactor CD147 of the spike protein could be involved.”
Preprint (not a paper): ‘Cerebral venous thrombosis: a retrospective cohort study of 513,284 confirmed COVID-19 cases and a comparison with 489,871 people receiving a COVID-19 mRNA vaccine’ by Maxime Taquet et al. This work is not peer-reviewed.
All our previous output on this subject can be seen at this weblink: